c-erbB2 amplification and overexpression in human tumors.
There is no evidence for activation of c-erbB2 by mutation in human cancer. Gene rearrangements are observed at low frequency, but there are a proportion of human cancers that are associated with c-erbB2 gene amplification and membrane protein overexpression. The human cancers so affected are adenocarcinomas of the breast, ovary, stomach, and bladder, with up to 20% of primary lesions exhibiting either increased gene copy number and/or excess membrane staining. The c-erbB2 protein on these tumors could be used as a therapeutic target, as in monoclonal antibody targetted therapy already being assessed in c-erbB2 positive breast cancer. Other possible therapeutic strategies include the development of tyrosine kinase inhibitors or ligand antagonists.
F J
FJ
Lofts
W J
WJ
Gullick
D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics; D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004790:Enzyme Induction; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics*; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics; D009857:Oncogenes; D009928:Organ Specificity; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics*; D011519:Proto-Oncogenes; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases
D009363:Neoplasm Proteins; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases